8-K filing — Advasa Holdings, Inc. (ADBT)
Filed: 2026-10-16 AccNo: 0001493152-26-047434 Size: 245 KB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Stocks · News reference
Cango, Nio And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session
U.S. stock futures were lower this morning, with the Dow futures falling around 200 points on Tuesday. Shares of Cango Inc (NYSE:CANG) fell sharply in pre-market trading as the company posted downbeat results for the
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Advasa Holdings Board Adopts Dividend Policy Targeting Annual Cash Dividend Payout Ratio Of 50% For Its Common Stock, Beginning With Fiscal Year Ending March 31, 2027
Advasa Holdings, Inc. (NASDAQ:ADBT) ("ADVASA" or the "Company"), a fintech payment holding company delivering Earned Wage Access ("EWA") and financial infrastructure solutions, today announced
Shares of enterprise software companies are trading higher amid an investor rotation from highly leveraged AI-exposed names into the legacy tech services sector. Fears of persistently high inflation and interest rates may increase the appeal of the industry's proven business models.
Advasa Announces FY2031 Targets Of $632.91M Revenue, $189.87M Operating Income, Rising From FY2027 Targets Of $18.99M, $1.9M
Lupus Nephritis Market on a Growth Trajectory at a CAGR of 7% During the Forecast Period (2026–2036), as Innovative Therapies Gain Momentum | DelveInsight
The lupus nephritis market is projected to grow at a 7% CAGR through 2036, driven by increasing disease awareness, improved diagnosis, and expanding adoption of targeted therapies. The market was valued at USD 2.1 billion in 2025 across seven major markets. Three therapies have received FDA approval (belimumab, voclosporin, and obinutuzumab), while a robust pipeline of innovative treatments including CAR-T therapies, complement inhibitors, and monoclonal antibodies is expected to transform disease management.
8-K filing — Cabaletta Bio, Inc. (CABA)
Filed: 2026-09-14 AccNo: 0001759138-26-000041 Size: 154 KB Item 8.01: Other Events